We are delighted to announce that Cambridge Bioscience has partnered with Amoy Diagnostics, a leading diagnostic company specialising in molecular diagnostics and precision medicine, with a focus on developing innovative diagnostic solutions primarily for cancer and infectious diseases. Amoy's portfolio includes assays based on PCR and next-generation sequencing (NGS) technology, enabling the detection of genetic mutations, biomarkers, and other molecular characteristics relevant to targeted therapies.
Cambridge Bioscience is pleased to distribute AmoyDx products in the UK and Ireland.
Published
08 Nov 2024